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Background and aims: Higher cortisol levels are associated with cardiovascular mortality in the elderly. It
is unclear whether this association also exists in a general population of younger adults and for non-fatal
cardiovascular events. Likewise, resting heart rate is associated with cardiovascular mortality, but fewer
studies have also considered non-fatal events. The goal of this study was to investigate whether twenty-
four-hour urinary cortisol (24-h UFC) levels and resting heart rate (RHR) predict major adverse fatal and
non-fatal cardiovascular events (MACE) in the general population.
Methods: We used data from a subcohort of the PREVEND study, a prospective general population based
cohort study with a follow-up of 6.4 years for 24-h UFC and 10.6 years for RHR. Participants were 3432
adults (mean age 49 years, range 28e75). 24-h UFC was collected and measured by liquid chromatog-
raphydtandem mass spectrometry. RHR was measured at baseline in a supine position for 10 min with
the Dinamap XL Model 9300. Information about cardiovascular events and mortality was obtained from
the Dutch national registry of hospital discharge diagnoses and the municipal register respectively.
Results: 24-h UFC did not signiﬁcantly increase the hazard of MACE (hazard ratio ¼ 0.999, 95% conﬁ-
dence interval ¼ 0.993e1.006, p ¼ 0.814). RHR increased the risk for MACE with 17% per 10 extra heart
beats per minute (hazard ratio ¼ 1.016, 95% conﬁdence interval ¼ 1.001e1.031, p ¼ 0.036) after
adjustment for conventional risk factors.
Conclusions: In contrast to 24-h UFC, RHR is a risk marker for MACE in the general population.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Psychosocial stress is awell-known risk factor for cardiovascular
disease (CVD) [1]. Hyperactivation of the hypothalamic-pituitary-
adrenal axis (HPA axis) and the sympathetic nervous system
(SNS), leading to increased cortisol levels and resting heart rate are
postulated to be amongst the mechanisms behind this association
[2].
This is plausible as cortisol has a direct effect on various risk
factors for CVD. Increased levels of cortisol can affect blood pres-
sure [3], BMI [4], waist circumference [4], fasting glucose levels [4],sychopathology and Emotion
al Center Groningen, P.O. Box
an Ockenburg).
r Ireland Ltd. This is an open accesand HDL levels [4]. Moreover, glucocorticoids may also adversely
inﬂuence remodeling after myocardial infarction via inhibition of
angiogenesis [5], and induction of ﬁbrosis via activation of the
mineralocorticoid receptor [6]. An elevated resting heart rate (RHR)
in turn might inﬂuence cardiovascular outcome by increasing car-
diac oxygen demand [7], decreasing coronary blood ﬂow by
decreasing the duration of the diastole [8], lowering endothelial
shear stress [9], and increasing the risk of plague rupture [10].
Two recent prospective studies showed that elevated levels of
cortisol predict cardiovascular death amongst elderly people with
[11] and without preexisting CVD [11,12]. To our knowledge, studies
in a younger population investigating whether physiological levels
of endogenous cortisol are associated with increased incidence in
cardiovascular events are lacking. Moreover, the studies in elderly
people did not investigate the relationship of cortisol levels with
non-fatal cardiovascular events. Regarding the effects of RHR, in
populations without known CVD, RHR was found to be a risk factors article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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although some studies did not ﬁnd any relationship with non-fatal
cardiovascular events [18e20].
In the current study we assessed for the ﬁrst time in a general
population cohort whether higher levels of cortisol are an inde-
pendent risk factor for major adverse fatal and non-fatal cardio-
vascular events (MACE). Moreover, we intended to replicate the
results of previous studies with regard to higher RHR and the risk
for MACE.
2. Materials and methods
2.1. Study population
We used data from a subcohort of the Prevention of REnal and
Vascular ENd stage Disease (PREVEND) study. PREVEND is popu-
lation cohort study originally designed to investigate micro-
albuminuria as a risk factor for renal disease and CVD. The
recruitment of participants for PREVEND has been extensively
described elsewhere [21]. In brief, 8592 subjects completed the
baseline screening survey in 1997e1998 (T1), rendering the PRE-
VEND study cohort. Subjects with insulin dependent diabetes
mellitus and pregnant women were excluded from the study
population. The PREVEND study is enriched for albuminuria which
is a risk factor for developing renal disease. To obtain a represen-
tative random sample of the Groningen general population for the
current study, we included all subjects with a urinary albumin
concentration (UAC) < 10 mg/L that completed the ﬁrst screening
(N ¼ 2592) and added a random subset (n ¼ 840) from the “over-
represented” subjects with an UAC> 10 mg/L proportional to the
degree of overrepresentation. This resulted in a group of 3432
subjects with a population representative ratio of albuminuria
negative and positive subjects forming the basis for the current
study. The average agewas 49 years, minimum andmaximumwere
28e75 years. Follow-upmeasurements took place between January
2002 and November 2003 (T2). Average time between T1 and T2
was 4.1 years. The study was approved by the local Medical Ethical
Committee for human research of the University Medical Center
Groningen (UMCG). All participants were aged 18 or older and
provided written informed consent for participation in this study.
2.2. 24-h urinary free cortisol
24-h urinary free cortisol (24-h UFC) was measured at T2. Par-
ticipants were asked to collect urine samples in a polypropylene
container on two consecutive days prior to the visit to the outpa-
tient clinic. They were carefully instructed to urinate into the
container during the 24-h collection period and refrigerate the
sample until delivery to the laboratory. 24-h urine collection was
available on at least one day for 2761 people and at both days for
2710 people. Urinary creatinine was measured to assess
completeness of the 24-h urine collection. We used the following
formula to assess completeness: incomplete urine 0.7 of [mmol
urinary creatinine 113]/[21 kilograms of body weight] [22], as
this has been proven to be the most sensitive method to detect
incompleteness [23]. Only samples which were complete according
to the above formula were used for the current study. Urinary free
cortisol (UFC) was measured by liquid chromatographydtandem
mass spectrometry (LCdMS/MS) analysis. The lower detection
limit of the assay was 0.3 nmol/l. At low, middle, and high con-
centrations, intra-assay variation ranged from 1.3 to 2.4% while
inter-assay variation ranged from 3.8 to 7.8%. 24-h UFC was calcu-
lated by multiplying urinary volume with cortisol concentration
and is expressed in nmol per 24-h. We used the mean of the two
samples on two consecutive days to reﬂect HPA axis function. In thecase when values of only one day were available we used this value
instead of the mean.
2.3. Resting heart rate
RHR and blood pressure Blood pressurewasmeasured, in supine
position, every minute for 10 min, with an automatic device
(Dinamap XL Model 9300, JohnsoneJohnson Medical, Tampa, FL,
USA).
2.4. Follow-up and outcomes
Information about cardiovascular events was obtained from the
Dutch national registry of hospital discharge diagnoses (PRISM-
ANT). Information about mortality was obtained from the munic-
ipal register. Information on the cause of death was acquired by
linking the number of death certiﬁcates to the primary cause of
death as coded by the Dutch Central Bureau of Statistics. The
outcome of interest was a combined end-point of fatal and non-
fatal major adverse cardiovascular events (MACE). MACE was
deﬁned as acute myocardial infarction (ICD-code 410), acute and
subacute ischemic heart disease (411), occlusion or stenosis of the
precerebral (433) or cerebral arteries (434) and the following pro-
cedures: coronary artery bypass grafting or percutaneous trans-
luminal coronary angioplasty, and other vascular interventions
namely percutaneous transluminal angioplasty or bypass grafting
of aorta and peripheral vessels. Mortality from any other cause was
censored.
2.5. Medication use
Medication (antihypertensive, lipid-lowering, antidiabetic) was
self-reported and substantiated with information of drug-use from
the IADB.nl, which contains dispensing information from 55 com-
munity pharmacies in the Northern part of the Netherlands,
covering on average 500 000 persons annually (www.IADB.nl) and
almost the entire population of PREVEND study participants [24].
The database's pharmacy information includes, among others,
name of the drug, anatomicetherapeuticechemical (ATC) classiﬁ-
cation and date of prescription. Medication records of patients are
virtually complete because of high patient pharmacy commitment
in the Netherlands [25] We extracted information on drug pre-
scriptions from 100 days prior until 100 days after the date of the
visit to our research facilities.
2.6. Covariates
Each survey in the PREVEND study consisted of one to two visits
to an outpatient unit. Participants completed a questionnaire on
demographics, CVD history, lifestyle and medication use before the
visit. Height and weight were measured and a fasting blood sample
was drawn. Body mass index was calculated as the ratio between
weight and height squared. Smoking status was assessed by self-
report. Participants were considered smokers if they had smoked
in the previous year and previous smokers if they had quit smoking
more than one year ago. Hypertensionwas deﬁned as systolic blood
pressure  140 mm Hg or diastolic blood pressure  90 mm Hg
following the Seventh Report of the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of High Blood
Pressure criteria, or use of antihypertensive medication. Hyperlip-
idemiawas deﬁned as cholesterol level>6.5mmol/L when a history
of hyperlipidemia was absent, or use of lipid-lowering drugs. Dia-
betes was deﬁned as fasting glucose level 7.0 mmol/L, nonfasting
glucose level 11.1 mmol/L, or use of antidiabetic medication. Prior
history of CVD at inclusion of the studywas deﬁned as self-report of
S.L. van Ockenburg et al. / Atherosclerosis 248 (2016) 44e5046cerebrovascular accident, coronary heart disease, or peripheral
vascular disease requiring surgery.
2.7. Statistical analysis
For statistical analysis, 24-h UFC and RHR were analyzed as a
continuous measure, and divided into quintiles to assess if the as-
sociation was linear. We used Cox proportional hazards regression
to investigate the associations between 24-h UFC or RHR (in
separate models), and the outcome variable MACE. Model 1 was
adjusted only for sex and age. Model 2 was additionally adjusted for
smoking status, hypertension, hyperlipidemia, diabetes mellitus,
and history of CVD. Model 3 was the same as model 2, but with
additional adjustment for creatinine clearance and BMI. The lowest
category (e.g. the 1st quintile) was always used as a reference
category. For sex, males were used as the reference category. The
use of corticosteroids leads to negative feedback on the HPA axis
and thus to lower endogenous levels of 24-h UFC. Thus, for the
analysis of 24-h UFC, we excluded participants using inhalation,
local, gastrointestinal, or systemic glucocorticosteroids (15%). For
the analyses on the effects of RHR, we excluded people on antihy-
pertensive medication (14%) as this might either directly (beta-
blocker, calcium channel blocker) or indirectly inﬂuence the values
of RHR. The proportional hazards assumption was checked by
graphically assessing the log-log minus function of all predictor
variables. The assumption was met for all predictor variables in all
analyses. Unlike RHR, 24-h UFC was not measured at baseline, but
only at the second assessment wave (T2). As any longitudinal study,
PREVEND suffered from some loss to follow-up. We therefore used
multiple imputation techniques to correct for attrition bias
(supplement 1). The conclusions drawn from the Cox regression
models on the original data and the imputed data sets were in
accordance with each other. The estimates below are pooled esti-
mates of the imputed data. Statistical analyses were performed
with IBM SPSS Statistics for Windows, Version 20.0. and Stata
Statistical Software: Release 12. StataCorp. A two-sided P value of
0.05 was considered statistically signiﬁcant.
3. Results
3.1. Population characteristics at T1 and T2
Descriptive statistics of the characteristics of our study popu-
lation at T1 and T2 are provided in Table 1. Therewere slightly more
women than men at T1 and T2 (56%). The average age at T1 was 49
years with a minimum of 28 and a maximum of 75 years. The
median follow-up time from T1 was 10.6 years and the median
follow-up time from T2 was 6.4 years. From T1 until follow-up in
January 2009, a total of 263 MACE took place. From T2 until follow-
up in January 2009 a total of 161 MACE took place. During the
PREVEND study, 588 T1 participants (17%) did not show up at the
follow-up visit (T2).
3.2. The prediction of MACE by 24-h urinary free cortisol
After excluding people on corticosteroidmedication, a sample of
2792 people remained, in which 121 MACE took place. Table 2
shows the results of the three Cox proportional hazard models
assessing the association between quintiles of 24-h UFC and MACE.
24-h UFC did not signiﬁcantly inﬂuence the hazard of MACE. The
traditional risk factors for MACE: sex, age, smoking status, hyper-
tension, hyperlipidemia, and previous history of CVD were all
highly signiﬁcant. To exclude the possibility that our negative
ﬁndings could be explained by the use of artiﬁcial cut-off scores, we
also ran two models adjusted only for sex and age with thecontinuous measure of 24-h UFC as a predictor. MACE was not
signiﬁcantly predicted by the continuous measure of 24-h UFC
(p ¼ 0.814). To investigate whether 24-h UFC levels might be only a
signiﬁcant predictor for people of a certain age, we also investi-
gated a model with a multiplicative interaction term between 24-h
UFC and age. The interaction term between 24-h UFC and age
(p¼ 0.791) was not statistically signiﬁcant. Likewise, an interaction
term between sex and 24-h UFC (p¼ 0.090) was not signiﬁcant. We
excluded the possibility that our null ﬁndings could be explained by
mixing a population with and without a history of CVD by rerun-
ning the analyses excluding persons with a history of CVD. After
excluding those with a history of CVD, a population of 2687 people
remained in which 97 MACE took place. 24-h UFC was again not a
signiﬁcant predictor of MACE (p ¼ 0.923).
3.3. The prediction of MACE by resting heart rate
After exclusion of persons using antihypertensive medication a
population of 2823 people remained, in which 156 MACE occurred.
Table 3 shows the results of the three Cox proportional hazard
models assessing the association between quintiles of RHR and
MACE. Compared to the lowest quintile, the risk for MACE was
twice as high in the fourth and the ﬁfth quintile while adjusting for
sex and age. Only the ﬁfth quintile of heart rate remained a sig-
niﬁcant predictor of MACE in the model adjusted for sex, age, hy-
pertension, smoking status, hyperlipidemia, diabetes mellitus, and
CVD history. In the ﬁnal model, with additional adjustment for BMI
and creatinine clearance, the ﬁfth quintile remained a signiﬁcant
predictor of MACE. We repeated the analyses for the continuous
variable of RHR (data not reported in table). Like the quintiles, the
continuous variable of RHR was a highly signiﬁcant predictor of
MACE while adjusting for sex and age (HR ¼ 1.074, 95%
CI ¼ 1.059e1.089, p < 0.001). After addition of hypertension,
smoking status, hyperlipidemia, diabetes mellitus, and CVD history
to themodel, the continuous variable of RHR remained a signiﬁcant
predictor of MACE, but its effects were attenuated (HR ¼ 1.016, 95%
CI¼ 1.001e1.031, p¼ 0.036). In the ﬁnal model, where also BMI and
creatinine clearance were added the continuous variable of heart
rate remained a signiﬁcant predictor, increasing the risk for MACE
with 16% per 10 extra heart beats per minute (HR ¼ 1.016, 95%
CI ¼ 1.001e1.031, p ¼ 0.036). We reran the same models after
exclusion of people with a history of CVD. In fully adjusted models,
the continuous variable of RHR (HR ¼ 1.016, 95% CI ¼ 1.001e1.031,
p ¼ 0.040) and the highest quintile (HR ¼ 2.073, 95%
CI ¼ 1.184e3.629, p ¼ 0.011) remained signiﬁcant predictors of
MACE in people without prior CVD.
4. Discussion
In the current study we investigated whether 24-h UFC levels
and RHR were independent predictors of major fatal and non-fatal
adverse cardiovascular events. Higher RHR did indeed signiﬁcantly
increase the risk of MACE. Unlike RHR and traditional cardiovas-
cular risk factors, 24-h UFC did not signiﬁcantly contribute to the
risk of MACE.
4.1. Limitations
There are several limitations that need to be considered when
interpreting our results. Heart rate is susceptible to inﬂuences from
the environment, and although it was measured in a very stan-
dardized way, with a 10-min recording, 24-h holter registration
could have increased accuracy. Moreover, as PREVEND is an
observational study, it can never establish a causal link, as residual
confounding might still exist. We did for instance not adjust for
Table 1
Population characteristics at T1 and T2.
Variable T1 T2
N ¼ 3432 N ¼ 2773a
MACE (N) 263 161
Myocardial infarction 72 40
(Sub)acute ischeamic heart disease 63 39
Occlusion or stenosis of:
- Precerebral arteries 14 8
- Cerebral arteries 27 19
CABG 22 14
PTCA 26 14
PTA of peripheral vessels 2 1
Bypass grafting of aorta 10 5
Carotid endarterectomy or carotid stenting 7 6
Death by MACE 20 15
Mean survival time MACE (SE) 3925 (12) 2719 (7)
Age 49 (12) 53 (12)
Sex (female) 56% 56%
Cortisol in nmol/24-h n.a. 69 (47e96)
Quintiles:
- 1st n.a. 1  UFC 43
- 2nd n.a. 43 < UFC 59
- 3rd n.a. 59 < UFC 79
- 4th n.a. 79 < UFC 106
- 5th n.a. 106 < UFC 666
Resting heart rate 69 (10) n.a.
Quintiles:
- 1st 42  RHR 61 n.a.
- 2nd 61 < RHR 66 n.a.
- 3rd 66 < RHR 71 n.a.
- 4th 71 < RHR 77 n.a.
- 5th 77 < RHR 115 n.a.
Smoking
 Never smoked 32% 32%
 Previous smoker 33% 40%
 Current smoker 35% 28%
BMI 26 (4) 27 (4)
Creatinine clearance 101 (26) 102 (25)
Hypertension 27% 28%
Diabetes (yes) 3% 5%
Hyperlipidemia (yes) 23% 22%
History of CVD (yes) 5% 4%
Antihypertensive medication (yes) 14% 18%
Glucocorticoid medication (yes) n.a. 15%
a Unimputed data after the exclusion of people with events before T2. CVD ¼ cardiovascular disease, BMI¼ body mass index, MACE¼ a
combined end-point of fatal and non-fatal Major Adverse Cardiovascular Event, N ¼ number of events, SE ¼ standard error of the mean,
CABG ¼ coronary artery bypass grafting, PTCA ¼ percutaneous transluminal coronary angioplasty, PTA ¼ percutaneous transluminal
angioplasty, UFC ¼ urinary free cortisol, RHR ¼ resting heart rate. Descriptives are given of non-missing values as either percentages or
mean with standard deviation between brackets unless indicated otherwise.
Table 2
Association of MACE with 24-h UFC in multivariable Cox regression models.a
Variable Model 1 Model 2 Model 3
HR 95% CI p HR 95% CI p HR 95% CI p
24-h UFC 2nd 0.741 0.253e2.170 0.583 0.820 0.273e2.469 0.724 0.823 0.273e2.479 0.728
24-h UFC 3rd 0.710 0.272e1.859 0.485 0.740 0.275e1.991 0.550 0.745 0.276e2.010 0.560
24-h UFC 4th 0.844 0.313e2.278 0.737 0.916 0.328e2.555 0.866 0.924 0.329e2.594 0.880
24-h UFC 5th 0.743 0.261e2.120 0.577 0.737 0.255e2.129 0.572 0.744 0.254e2.180 0.588
Age 1.086 1.068e1.104 <0.001 1.064 1.043e1.087 <0.001 1.063 1.039e1.087 <0.001
Sex (female) 0.382 0.258e0.564 <0.001 0.457 0.302e0.692 <0.001 0.444 0.285e0.690 <0.001
Previous smoker 1.306 0.709e2.405 0.391 1.309 0.711e2.411 0.387
Current smoker 2.768 1.532e5.001 0.001 2.757 1.523e4.933 0.001
Hypertension 2.515 1.467e4.310 0.001 2.534 1.459e4.401 0.001
Diabetes 1.307 0.692e2.470 0.408 1.308 0.691e2.477 0.409
Hyperlipidemia 1.564 1.020e2.398 0.040 1.566 1.012e2.393 0.044
CVD history 1.896 1.124e3.199 0.017 1.871 1.101e3.180 0.021
BMI 0.999 0.947e1.054 0.979
Creatinine clearance 0.998 0.987e1.009 0.726
a After exclusion of people on corticosteroid. medication. BMI ¼ body mass index, 24-h UFC ¼ twenty-four-hour urinary free cortisol, CVD ¼ cardiovascular disease,
HR ¼ hazard ratio, 95% CI ¼ 95% conﬁdence interval of the hazard ratio, p ¼ p-value.
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Table 3
Association of MACE with resting heart rate in Multivariable Cox Regression Models.a
Variable Model 1 Model 2 Model 3
HR 95% CI p HR 95% CI p HR 95% CI p
RHR 2nd 1.707 0.990e2.943 0.054 1.643 0.953e2.833 0.074 1.654 0.948e2.885 0.076
RHR 3rd 1.026 0.541e1.948 0.936 0.879 0.462e1.675 0.695 0.895 0.467e1.716 0.738
RHR 4th 2.026 1.180e3.476 0.010 1.592 0.920e2.754 0.096 1.635 0.938e2.850 0.083
RHR 5th 2.626 1.569e4.397 <0.001 1.942 1.151e3.276 0.013 1.934 0.137e3.290 0.015
Age 1.074 1.059e1.089 <0.001 1.073 1.056e1.090 <0.001 1.067 1.049e1.084 <0.001
Sex (female) 0.275 0.193e0.391 <0.001 0.295 0.205e0.424 <0.001 0.260 0.147e0.386 <0.001
Previous smoker 1.246 0.751e2.066 0.395 1.277 0.763e2.138 0.351
Current smoker 3.104 1.957e4.925 <0.001 3.252 2.034e5.202 0.001
Hypertension 1.337 0.940e1.900 0.106 1.286 0.887e1.845 0.172
Diabetes 0.943 0.384e2.312 0.897 0.942 0.383e2.138 0.897
Hyperlipidemia 2.010 1.454e2.788 <0.001 1.987 1.434e2.753 <0.001
CVD history 1.733 0.948e3.168 0.074 1.704 0.930e3.121 0.085
BMI 1.049 1.002e1.098 0.040
Creatinine clearance 0.993 0.986e1.001 0.074
a After exclusion of people who use antihypertensive medication. BMI ¼ body mass index, RHR ¼ resting heart rate, CVD ¼ cardiovascular disease, HR ¼ hazard ratio, 95%
CI ¼ 95% conﬁdence interval of the hazard ratio, p ¼ p-value.
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heart rate [26] and cardiovascular outcomes. A recent study
demonstrated, however, that heart rate is an independent risk
factor for mortality after adjustment for cardiorespiratory ﬁtness as
indexed by VO2-max [13]. Another limitation of the current study is
that the PREVEND study suffered from attrition and no-show at the
scheduled follow-up visit at T2 at which 24-h UFC was measured.
Individuals with missing data had in general more cardiovascular
risk factors and experiencedmore events. As participants needed to
be event free until the second survey to be included in the current
study, our negative results might also in part be due to a survivor
selection bias. Furthermore, the occurrence of death from other
than cardiovascular causes might have precluded participants from
experiencing MACE (competing risk phenomena). These limita-
tions, however, also apply to previous cohort studies. In the
INCHIANTI and the WHITEHALL II study missingness was also
related to lower socioeconomic status and having more cardio-
vascular risk factors. Complete case analysis can yield biased esti-
mates [27]. Unlike the two other studies, we used multiple
imputation to mitigate the effects of missingness and to preserve
power as is advised also for survival analysis [27,28]. The outcome
MACE was known for every participant including those that had
dropped out. Yet, our conclusion remained the same with both
complete case analysis and analyses of the imputed sets. We can,
however, never exclude the possibility that selection bias nega-
tively inﬂuenced our results.4.2. Strengths
The PREVEND study also has several strengths. It is a large
population representative cohort in which both predictors and
outcomes were well measured. MACE were assessed by using the
Dutch national registry of hospital discharge diagnoses and the
Dutch national bureau of statistics. Therefore, detailed information
was available on both fatal and non-fatal events. Furthermore,
medication use was substantiated with information from the
database of pharmacy-dispensing data. Compared to the
INCHIANTI study, the only other study which measured 24-h UFC,
the PREVEND study has some important methodological strengths.
Firstly, in our study, in the majority of cases, 24-h UFC was
measured on two consecutive days thus giving a more reliable es-
timate of 24-h UFC levels, whereas in the INCHIANTI study only one
day of 24-h urine was available. Secondly, we were able to verify
completeness of the samples by measuring urinary creatinineexcretion. We had to exclude 16% of the samples based on this
analysis. In the INCHIANTI study, compliance was assessed by self-
report and therefore only 2.7% of samples was excluded. Thirdly, in
the INCHIANTI study 24-h UFC was measured by Bayer's ADVIA-
Centaur immunoassay system which has poor speciﬁcity due to
cross-reactivity with cortisone (44%) and is sensitive to drug
interference [29]. In PREVEND, 24-h UFC was measured by means
of LC-MS/MS which is free of interferences from cortisol metabo-
lites and conjugates, and also eliminates drug interferences [30].4.3. Cortisol levels and cardiovascular outcomes
Three studies investigated the relationship between cortisol
levels and cardiovascular mortality [11,12,31] Two found cortisol
levels to be predictive of cardiovascular mortality (a ﬂatter slope of
salivary cortisol levels over the day [12] in the WHITEHALL II, or
higher levels of 24-h UFC [11] INCHIANT study respectively).
Whereas one, the Vietnam Experience study, did not ﬁnd an as-
sociation between serum cortisol levels and cardiovascular mor-
tality [31]. None of these studies took non-fatal events into account
as we did. Yet, if higher cortisol levels really do increase the risk of
CVD one would expect to also ﬁnd an association with non-fatal
events, which we did not. Our negative results cannot be
explained by a lack of events. In the WHITEHALL II study and the
CHIANTI study 32 and 41 fatal cardiovascular events took place
respectively, whereas in PREVEND 121 MACE took place. In general
10 events per predictor variable are needed to get reliable regres-
sion estimates [32]. Lacking events does not just decrease power to
detect a true effect, but also biases regression coefﬁcients, and can
also lead to an overestimation of the hazard [32]. The PREVEND
study differs from WHITEHALL II and the INCHIANTI study on
several other aspects. In terms of average age (52 years at T2)
PREVEND has a relatively young population compared to the
aforementioned studies, where the average participant was older
than 65 years. Furthermore, PREVEND is a general population based
cohort, whereas participants in WHITEHALL II were white collar
workers, and the participants of the INCHIANTI study were all
retired. It might thus be that cortisol forms a risk for cardiovascular
events only in an elderly population. We tested for this possibility
by including and interaction term between 24-h UFC and age into
our model, but found no statistical support for this hypothesis.
An explanation for our null ﬁndings might be that within-
individual stability of cortisol levels are low. The few studies that
assessed intra-individual stability of cortisol levels over longer
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ability [33,34]. This would make it difﬁcult to detect a true effect of
24-h UFC on MACE. Perhaps longer term indices of within-person
levels of cortisol, such as cortisol measured in scalp hair [35], are
more suitable to study the relationship between HPA-axis func-
tioning and the occurrence of MACE.
4.4. Resting heart rate and cardiovascular outcomes
In patients with CVD, higher RHR has consistently been found to
predict cardiovascular mortality [18,20,36,37]. In the current study,
we demonstrated in a relatively young and healthy population that
RHR increases the risk of fatal and nonfatal MACE while adjusting
for various conventional risk factors. Our study adds to the accu-
mulating epidemiological evidence from general population co-
horts that RHR is a signiﬁcant predictor of fatal and non-fatal
cardiovascular outcomes in populations without preexisting CVD
[13e15,17,38,39]. In patients with stroke, RHR has been demon-
strated to increase the risk of myocardial infarction [37]. Several
other studies failed to demonstrate a signiﬁcant relationship be-
tween RHR and non-fatal cardiac events in patients with a history
of CVD [18e20]. From the literature it is unclear whether the
relationship between RHR and cardiovascular outcomes is linear.
Some studies have demonstrated a J-shaped relationship [40] or
threshold effect [36], whereas others showed a clear linear rela-
tionship [18,41]. Our study suggests that there might be threshold
effect because, when examining quintiles of RHR, only people with
a RHR larger than 77 beats per minute had an increased risk of
MACE after adjusting for conventional risk factors. New results
from the Multi-Ethnic Study of Atherosclerosis point in the same
direction, with only people who have a RHR larger than 80 beats
per minute having a higher risk of MACE [42]. Based on these re-
sults a cut-off value for RHR of 80 beats per minute in the general
population seems reasonable to classify a low and a high-risk
group. Future studies should examine in other cohorts whether
adding RHR to existing risk scores improves its discriminative
power.
The question arises whether RHR is a modiﬁable risk factor or
epiphenomena, meaning it is only a risk marker. For certain patient
groups RHR seems to be a modiﬁable risk factor, as reduction of
heart rate has proven to be protective against cardiovascular mor-
tality in patients with left ventricular failure. For instance, in the
BEAUTIFUL study, heart rate reduction with Ivabradine, a selective
inhibitor of the If current, was shown to decrease the risk of car-
diovascular death in patients with coronary artery disease and left
ventricular dysfunction who had a RHR> 70 beats per minute [41].
Likewise, in the SHIFT study, in patients with systolic heart failure,
heart rate reduction with Ivabradine led to a decrease in cardio-
vascular deaths and hospitalizations [43]. In contrast, results from
the SIGNIFY study make it clear that for patients with stable cor-
onary artery disease without clinical heart failure, RHR seems to
merely be a risk marker, as lowering heart rate did not improve
clinical outcomes [44].
In conclusion, RHR is a strong riskmarker of MACE in the general
population without pre-established CVD. This might have clinical
implications, as the measurement of heart rate is a non-invasive
low-cost procedure that could easily be used to detect people
that are at heightened risk for a cardiovascular event. Finally, we
did not ﬁnd any evidence that higher urinary cortisol levels in-
crease the risk of MACE.
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